

## Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

### Supplementary Materials

**Supplementary Table 1: Mutational marker reported in the mutational profiling group**

	Mutation groups (N = 78)	
	N	%
<b><i>EGFR</i></b>		
Wild-type	69	88
Mutant	9	12
<b><i>KRAS</i></b>		
Wild-type	66	85
Mutant	12	15
<b><i>BRAF</i></b>		
Wild-type	62	79
Mutant	3	4
Missing*	13	17
<b><i>PIK3CA</i></b>		
Wild-type	56	72
Mutant	1	1
Missing*	21	27
<b><i>HER2</i></b>		
Wild-type	62	79
Mutant	0	-
Missing*	16	21
<b><i>NRAS</i></b>		
Wild-type	31	40
Mutant	1	1
Missing*	46	59
<b><i>ALK</i> (FISH test)</b>		
Positive	2	3
Negative	49	63
Missing*	27	35

\*When the mutation rate was < 5% in the dataset, missing values were considered as wild-type.

**Supplementary Table 2: Type of failure description according to mutation group**

	All wild-type		EGFR/ALK		Other mutation	
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%
Locoregional	12	24	2	18	2	12
Metastatic	11	22	4	36	5	29
Locoregional + metastatic*	15	30	4	36	6	35
Death without progression	3	6	0	-	3	18
Alive without progression	9	18	1	9	1	6

\*Apparition of metastatic relapse less than 3 months after the diagnosis of loco-regional relapse.